Send us a text A lab surprise turned frontline hope: we sit down with Dr Liz Dallimore, CEO of Argenica Therapeutics, to unpack a peptide drug designed to protect the brain during the chaotic minutes after stroke and other injuries. Built from a chain of arginines, the therapy targets the glutamate‑driven calcium surge that kills neurons, aiming to stabilise tissue while clot dissolvers or thrombectomy restore blood flow. We trace Argenica’s journey from Perth lab benches to a multi‑centre P...
All content for ASX BRIEFS is the property of Andrew Musgrave and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text A lab surprise turned frontline hope: we sit down with Dr Liz Dallimore, CEO of Argenica Therapeutics, to unpack a peptide drug designed to protect the brain during the chaotic minutes after stroke and other injuries. Built from a chain of arginines, the therapy targets the glutamate‑driven calcium surge that kills neurons, aiming to stabilise tissue while clot dissolvers or thrombectomy restore blood flow. We trace Argenica’s journey from Perth lab benches to a multi‑centre P...
TUNGSTEN MINING NL (TGN) - Can Australia secure the world’s tungsten future?
ASX BRIEFS
8 minutes
2 weeks ago
TUNGSTEN MINING NL (TGN) - Can Australia secure the world’s tungsten future?
Send us a text Prices are surging, supply is squeezed, and buyers are searching for reliable sources of tungsten outside China and Russia. We sit down with Gary Lyons, Non‑Executive Chair of Tungsten Mining, to unpack how Mt Mulgine in Western Australia could become a cornerstone supplier for hardmetals, aerospace, energy, and defence—while using near‑term gold to fund the path to scale. Gary takes us inside the market fundamentals: China at roughly 80% of concentrate, Russia near 10%, expor...
ASX BRIEFS
Send us a text A lab surprise turned frontline hope: we sit down with Dr Liz Dallimore, CEO of Argenica Therapeutics, to unpack a peptide drug designed to protect the brain during the chaotic minutes after stroke and other injuries. Built from a chain of arginines, the therapy targets the glutamate‑driven calcium surge that kills neurons, aiming to stabilise tissue while clot dissolvers or thrombectomy restore blood flow. We trace Argenica’s journey from Perth lab benches to a multi‑centre P...
